Dudnik E, Moskovitz M, Agbarya A, et al. - Because nivolumab cessation after 12 months (mo) in aNSCLC has a negative impact on results, researchers evaluated the value of continuing nivolumab as well as the optimal dosing beyond 24mo in this world data‐based analysis. They included 45 patients treated with nivolumab for ≥ 24mo out of 697 consecutive patients with aNSCLC who started nivolumab between 2015‐2018. Participants were grouped as follows: nivolumab given at 3 mg/kg q2 weeks (w)/240 mg q2w/480 mg q4w (Group A; n = 25); nivolumab re‐scheduled to a non‐standard dose 3 mg/kg q3w‐q8w, (Group B; n = 13); nivolumab cessation following 24mo, (Group C; n = 7); (in groups B and C ‐ for reasons other than progressive disease or intolerable toxicity). At 36 months after nivolumab start, groups A, B, C, and B + C demonstrated a PFS of 100%, 67%, 67% and 67%, respectively, while PFS at 40 months after nivolumab initiation was 83%, 67%, 67% and 67%, respectively. Overall, alternative nivolumab scheduling or quitting 24mo post-initiation was found to be associated with a trend for worse PFS. The standard treatment choice of continuing nivolumab at a standard dose until disease advancement or intolerable toxicity remains.